The diagnostic value of 124I-PET in patients with differentiated thyroid cancer

Phan, Ha T. T.; Jager, Pieter L.; Paans, Anne M. J.; Plukker, John T. M.; Sturkenboom, M. G. G.; Sluiter, W. J.; Wolffenbuttel, Bruce H. R.; Dierckx, Rudi A. J. O.; Links, Thera P.
May 2008
European Journal of Nuclear Medicine & Molecular Imaging;May2008, Vol. 35 Issue 5, p958
Academic Journal
The purpose of this prospective study was to evaluate the clinical diagnostic value of iodine-124 (124I)-positron emission tomography (PET) in patients with advanced differentiated thyroid carcinoma (DTC) and to compare the 124I-PET imaging results with the 131I whole-body scan (WBS). Twenty patients with histologically proven advanced DTC (including T4, extra-nodal tumour growth, or distant metastases) underwent diagnostic 131I-WBS, 124I-PET scan, and post-treatment 131I-WBS 4 months after ablation. The findings on the 124I-PET were compared with the findings on the diagnostic and post-therapeutic 131I-WBS and were also correlated with radiologic and/or cytological investigations. 124 I-PET vs diagnostic 131 I-WBS. Eleven patients showed uptake on the 124I-PET. Only 3 of these 11 patients also showed uptake on the diagnostic 131I scan, but the uptake was more clearly visible and the abnormalities were more extensive on the 124I-PET. 124 I-PET vs post-treatment 131 I-WBS. Eleven patients showed uptake on the 124I-PET, which was also visible on the post-treatment scan in nine patients; in the other two patients, no uptake was observed on the post-treatment scan and no anatomical localisation could be confirmed. Two patients showed only uptake on the post-treatment scan without uptake on the 124I-PET: in one, the uptake was confirmed by MRI, and in the other, no anatomical localisation was found. In seven patients, no uptake was observed on both the scans. 124I-PET proved to be a superior diagnostic tool as compared to low-dose diagnostic 131I scans and adequately predicted findings on subsequent high-dose post-treatment 131I scans.


Related Articles

  • 13N-ammonia myocardial perfusion imaging with a PET/CT scanner: impact on clinical decision making and cost-effectiveness. Siegrist, Patrick T.; Husmann, Lars; Knabenhans, Martina; Gaemperli, Oliver; Valenta, Ines; Hoefflinghaus, Tobias; Scheffel, Hans; Stolzmann, Paul; Alkadhi, Hatem; Kaufmann, Philipp A. // European Journal of Nuclear Medicine & Molecular Imaging;May2008, Vol. 35 Issue 5, p889 

    The purpose of the study is to determine the impact of 13N-ammonia positron emission tomography (PET) myocardial perfusion imaging (MPI) on clinical decision making and its cost-effectiveness. One hundred consecutive patients (28 women, 72 men; mean age 60.9 ± 12.0 years; range 24–85...

  • [18F]FBEM-ZHER2:342–Affibody molecule—a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Kramer-Marek, Gabriela; Kiesewetter, Dale O.; Martiniova, Lucia; Jagoda, Elaine; Sang Bong Lee; Capala, Jacek // European Journal of Nuclear Medicine & Molecular Imaging;May2008, Vol. 35 Issue 5, p1008 

    The expression of human epidermal growth factor receptor-2 (HER2) receptors in cancers is correlated with a poor prognosis. If assessed in vivo, it could be used for selection of appropriate therapy for individual patients and for monitoring of the tumor response to targeted therapies. We have...

  • Evaluation of 2′-deoxy-2′-[18F]fluoro-5-methyl-1-β- l-arabinofuranosyluracil ([18F]- l-FMAU) as a PET imaging agent for cellular proliferation: comparison with [18F]- d-FMAU and [18F]FLT. Nishii, Ryuichi; Volgin, Andrei; Mawlawi, Osama; Mukhopadhyay, Uday; Pal, Ashutosh; Bornmann, William; Gelovani, Juri; Alauddin, Mian // European Journal of Nuclear Medicine & Molecular Imaging;May2008, Vol. 35 Issue 5, p990 

    Clevudine ( l-FMAU) an un-natural analogue of thymidine, is in clinical trials for the treatment of hepatitis B virus (HBV). l-FMAU is phosphorylated by cellular kinases such as thymidine kinase 1 and deoxycytidine kinase, and its triphosphate form inhibits HBV deoxyribonucleic acid synthesis....

  • Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. Gómez-Río, Manuel; Rodríguez-Fernández, Antonio; Ramos-Font, Carlos; López-Ramírez, Escarlata; Llamas-Elvira, José // European Journal of Nuclear Medicine & Molecular Imaging;May2008, Vol. 35 Issue 5, p966 

    Reliable differential diagnosis between tumour recurrence and treatment-induced lesions is required to take advantage of new therapeutic approaches to recurrent gliomas. Structural imaging methods offer a high sensitivity but a low specificity, which might be improved by neurofunctional imaging....

  • Role of positron emission tomography-computed tomography in bronchial mucoepidermoid carcinomas: a case series and review of the literature. Jindal, Tarun; Kumar, Arvind; Kumar, Rakesh; Dutta, Roman; Meena, Monika // Journal of Medical Case Reports;2010, Vol. 4 Issue 1, p1 

    Introduction: Mucoepidermoid carcinoma of the tracheobronchial tree is rare. Such tumors usually present with signs and symptoms of bronchial obstruction. Histologically, they can be classified as high-grade or low-grade tumors. Experience of imaging these tumors with 18fluorodeoxyglucose...

  • Improved tolerance to missing data in myocardial perfusion SPET using OSEM reconstruction. Hatton, R.L.; Hutton, B.F.; Angelides, S.; Choong, K.K.L.; Larcos, G. // European Journal of Nuclear Medicine & Molecular Imaging;2004, Vol. 31 Issue 6, p857 

    When projection data are incomplete for various technical reasons, artefacts may occur in the reconstructed images. This study examines whether an iterative reconstruction method, the ordered subsets implementation of the EM algorithm (OSEM), can improve reconstruction and minimise the artefacts...

  • Should we use more PET–CT in clinical cardiology? Knuuti, J. // European Journal of Nuclear Medicine & Molecular Imaging;May2008, Vol. 35 Issue 5, p887 

    The author reflects on the issue concerning the use of positron emission tomography (PET) and computed topography (CT) in clinical cardiology. He recounts on the several advantages of PET in the increase of specificity and accuracy in detection of coronary artery disease (CAD). He further...

  • Fluorine-18-Labelled Fluoropyridines: Advances in Radiopharmaceutical Design. Dollé, F. // Current Pharmaceutical Design;Sep2005, Vol. 11 Issue 25, p3221 

    Positron Emission Tomography is a high-resolution, sensitive, functional imaging technique, which can efficiently give access to the distribution, pharmacokinetics and -dynamics of a drug in vivo and which can therefore advantageously play a key-role in both drug discovery and development. This...

  • PET Imaging in Clinical Drug Abuse Research. Gatley, S. John; Volkow, Nora D.; Gene-Jack Wang; Fowler, Joanna S.; Logan, Jean; Yu-Shin Ding; Gerasimov, Madina // Current Pharmaceutical Design;Sep2005, Vol. 11 Issue 25, p3203 

    Over the last two decades, SPECT (single photon emission computed tomography) and especially PET (positron emission tomography) have proven increasingly effective imaging modalities in the study of human psychopharmacology. Abusing populations can be studied at multiple times after abstinence...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics